By Ben Glickman Invea Therapeutics has filed for an initial public offering with the Securities and Exchange Commission. The Guilford, Conn.-based company is.
BioXcel Therapeutics (NASDAQ:BTAI – Free Report) had its target price cut by Bank of America from $43.00 to $23.00 in a research report sent to investors on Friday morning, The Fly reports. Several other brokerages have also commented on BTAI. Mizuho boosted their price target on shares of BioXcel Therapeutics from $38.00 to $40.00 in […]
BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Rating) saw a large growth in short interest during the month of May. As of May 31st, there was short interest totalling 3,720,000 shares, a growth of 11.0% from the May 15th total of 3,350,000 shares. Based on an average daily volume of 596,900 shares, the short-interest ratio is […]
Shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Rating) have received an average rating of “Moderate Buy” from the seven ratings firms that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12 month […]